Table 2.
Procedural characteristics of patients with TAVI-related infective endocarditis
| Procedural characteristics |
Total
( n = 733) |
TAVI-IE
( n = 17) |
TAVI-NIE
( n = 716) |
p value |
|---|---|---|---|---|
| Valve morphology | ||||
| Tricuspid | 678 (92.4) | 15 (88.2) | 663 (92.5) | 0.36 |
| Bicuspid | 28 (3.8) | 1 (5.8) | 27 (3.7) | 0.48 |
| Valve-in-valve | 27 (3.6) | 1 (5.8) | 26 (3.6) | 0.47 |
| TAVI access site | ||||
| Transfemoral | 680 (92.7) | 17 (100) | 663 (88.4) | 0.62 |
| Transapical | 31 (4.2) | - | 31 (4.3) | 1.0 |
| Trans-septal | 10 (1.3) | - | 10 (1.3) | 1.0 |
| Trans-subclavian | 6 (0.8) | - | 6 (0.8) | 1.0 |
| Transcaval | 4 (0.5) | - | 4 (0.5) | 1.0 |
| Transcarotid | 1 (0.1) | - | 1 (0.1) | 1.0 |
| Transaxillary | 1 (0.1) | - | 1 (0.1) | 1.0 |
| TAVI prosthesis | ||||
| Edwards* | 581 (79.1) | 11 (64.6) | 570 (79.6) | 0.13 |
| Medtronic** | 98 (13.2) | 4 (23.5) | 94 (13.1) | 0.21 |
| ACURATE Neo | 44 (6.0) | 2 (11.7) | 42 (5.8) | 0.31 |
| JenaValve | 10 (1.4) | 0 (0) | 10 (1.4) | 1.0 |
| Procedural duration (min) | 82 ± 38 | 90 ± 33 | 82 ± 38 | 0.38 |
| New PPM implant | 45 (6.1) | 3 (17.6) | 42 (5.86) | 0.08 |
Value are presented as mean ± standard deviation or n (%)
IE infective endocarditis, NIE no infective endocarditis, Valve-in-valve TAVI implanted within a previous bioprosthetic aortic valve, PPM permanent pacemaker
*Sapien, Sapien 3, Sapien XT
**Evolut R, Evolut Pro, CoreValve